Real-world polypharmacy and healthcare resource utilization after early-line treatment with cannabidiol for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex

Real-World Dose Trajectory Patterns and Impact on Polypharmacy Burden and New Antiseizure Medication (ASM) Prescriptions in Patients With Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS), or Tuberous Sclerosis Complex (TSC) Receiving Cannabidiol (CBD)

Assessing artificial censoring weights for clone censor weighting studies: A simulation-based approach

Patterns of Remdesivir Initiation in Immunocompromised Patients Hospitalized With COVID-19

Effect of Cannabidiol on Antiseizure Medication Cycling, Polypharmacy, and Healthcare Resource Utilisation in Patients With Dravet Syndrome, Lennox-Gastaut Syndrome, or Tuberous Sclerosis Complex: Real-World Data from a US Claims Analysis